Background
==========

Real-time quantitative reverse transcription PCR (RT-QPCR) has become a method of choice for gene expression profiling in a large number of applications. However, obtaining reliable measurements still depends on the choice of control genes on which the baseline level is constructed. Selecting the control genes remains a critical point in the normalization process. Often, a short list of candidates is produced based on non-systematic and/or often poorly defined biological considerations.

In early studies, normalization was usually based on a single control gene. More recently, the trend is to use several control genes whose average expression level (on a log-scale) is used as baseline \[[@B1],[@B2]\]. Suitable control genes are selected from a short list of 10--15 genes by ranking them according to a criterion that essentially selects those genes having low variation across samples. We describe brie y a few such methods below.

\[[@B2]\] introduces a stability coefficient which is used along with the coefficient of variation for ranking the genes from a predefined list of candidates. Gene stability is defined in terms of average standard deviation of the log-ratios of pairs of candidate genes. Genes are ranked by iteratively removing those most unstable. This approach has the drawback that repeated comparison of pairs of genes is required, which is feasible only when the number of candidates is small. In addition, the method implicitly assumes that there are no co-regulated genes. A model-based approach proposed by \[[@B1]\] aims at estimating the overall variation as well as the between sample variation of each candidate gene. However, with this approach it is cumbersome to integrate different platforms. In an application to plant pathogen profiling, \[[@B3]\] investigates a list of 18 pre-selected candidate housekeeping genes, using the method proposed in \[[@B2]\] and RT-QPCR for measuring the gene expressions. \[[@B4]\] proposes a PCA-based statistical analysis to identify the most suitable control genes among 13 candidates which were selected such that they had independent functions in cellular maintenance.

\[[@B5]\] introduces a strategy which combines the coefficient of variation, maximum fold change and mean expression value in a ranking criterion that is applied to a large number of samples representing a wide variety of tissues. All these samples were hybridized on either Affymetrix HG-U133A or HG-U133 Plus 2.0 arrays and quantile-normalized together prior to ranking. Only probesets common to both arrays were used, with probesets targeting the same gene averaged into a single value.

There are some important differences between the methods described above and our approach (described below). Firstly, in contrast with all the studies based on PCR, we do not require a short list of candidate genes to be produced before assessing their suitability as control genes. Instead, we screen all the genes represented on the microarray chips, giving us the opportunity to assess genes that have not been reported previously. Moreover, we take a meta-analytical approach to the problem, first creating an independent ranking within each data set then aggregating these rankings into a single list. This approach has the advantage of being platform- and normalization-independent. In addition, the approach is not limited to using only genes common between different data sets. Also, by not using the coefficient of variation, we can treat uniformly both single and two-colors arrays. Thus, we are able to exploit data obtained from different platforms without requiring them to be normalized together. Furthermore, the meta-analytical approach allows us to integrate gene lists produced using our ranking system with other ranked gene lists from the literature and we do not require all data to be normalized together. Another key difference is that we introduce a new stability coefficient that combines the mean expression and the standard deviation in a ranking criterion that corresponds to our requirements for candidate control genes for RT-QPCR. In general, these requirements are:

• low variability across different specimens (*e.g*., subtypes of tumors or normal tissues);

• high and moderate level of expression, such that control genes with expression levels across a larger range may be selected;

• consistency across experiments and platforms.

A key question is whether it is possible to select genes from microarray studies that perform as control genes on PCR platform, given that the two technologies are different. We hypothesize that translating the list of candidate genes from microarray to PCR platform is feasible and we provide empirical evidence in this sense.

Results
=======

Data sets and pre-processing steps
----------------------------------

We have collected ten publicly available data sets \[[@B6]-[@B15]\], listed in Table [1](#T1){ref-type="table"}, from which we derived the quantities of interest: the mean and standard deviations of the log-intensities (on Affymetrix platforms) or of the log-ratios (on Agilent platforms).

###### 

The ten public microarray data sets used (*n*= number of samples).

  Data set ID and reference   *n*    Platform
  --------------------------- ------ ----------------------
  BWH \[[@B6]\]               47     Affymetrix U133v2
  EMC \[[@B7]\]               286    Affymetrix U133A
  EXPO \[[@B8]\]              1375   Affymetrix U133Plus2
  JRH2 \[[@B9]\]              61     Affymetrix U133A
  MGH \[[@B10]\]              60     Agilent
  NKI \[[@B11]\]              337    Agilent (custom)
  STOCK \[[@B12]\]            159    Affymetrix U133A, B
  TGIF1 \[[@B13]\]            49     Affymetrix U133A
  UNC \[[@B14]\]              153    Agilent HuA1
  UPP \[[@B15]\]              249    Affymetrix U133A, B

We note here that the original EXPO data set contains a number of different pathologies, but we restrict analysis here to eight different types of cancer (breast, colon, endometrium, kidney, lung, ovary, prostate and uterus) for which a sufficient number of samples existed. EXPO breast cancer samples (*n*= 328) were used to produce both the breast cancer and general cancer lists of candidate genes.

The Affymetrix data are available as MAS5.0 normalized values. The Agilent data contains log-ratios (base 10) and mean-centered log-intensities. The standard deviations of log-intensities (Affymetrix) and log-ratios (Agilent) were used as measures of variability. The means of log-intensities (both Affymetrix and Agilent) were used as measures of average expression level.

When multiple probesets of the same gene are present, only the most variable one is used. We consider all genes from each platform, the aggregation methods used being able to cope with \'missing\' genes (those not represented on the array). Considering only those genes common to all platforms is an unnecessary limiting constraint, as increasing the number of data sets and the heterogeneity of the collection leads to a successively smaller intersection of genes.

Before any further usage of the data, we reduce the variability across platforms by scaling with a factor given by a first order LOESS fit of the data. The effect of this transformation can be seen in Figure [1](#F1){ref-type="fig"}, where the black line represents the fitted curve. This simple approach seems effective, except for genes with low expression. However, as we are interested in genes with higher mean expression, this deficiency is not problematic.

![**Example of variance stabilization by LOESS correction**. LOESS correction applied to three data sets: BWH, NKI and EXPO-breast, respectively. The first row shows the original data with the fitted first order LOESS curve, while the second row shows the variance-stabilized data.](1471-2105-10-42-1){#F1}

Ranking the genes
-----------------

Let us consider that we have *M*microarray data sets, each containing expression values of a set of genes *G*~*k*~, *k*= 1,\...,*M*, and let *G*= ∪~*k*~*G*~*k*~= {1,\...,*N*} be the set of all genes represented at least once in any of these data sets.

### Gene scores

We aim to design a scoring function which ranks the genes such that higher scores correspond to genes that are more suitable to be used as control genes. As mentioned above, the score has to combine each gene\'s mean expression and standard deviation into a single value such that higher expression levels and lower variances (standard deviations) are favored. Moreover, the score must be independent of the technology used to measure expression levels and the method for normalization.

These requirements lead us to propose a new *stability score*for the gene expression levels. This score for gene *i*in data set *k*, denoted *s*~*ik*~, is defined as

$$s_{ik} = \alpha{\log}_{2}(\max\left\{ {\hat{\mu}}_{ik} - \beta_{k},0 \right\}) - {\hat{\sigma}}_{ik},$$

where ${\hat{\mu}}_{ik}$ and ${\hat{\sigma}}_{ik}$ are the estimated mean log-intensity and the standard deviation of the gene *i*in data set *k*. The *α*coefficient allows the user to control the trade-off between the mean expression and the standard deviation in gene scoring. Results reported here were obtained with *α*= 0.25. The *β*~*k*~parameter allows one to define the level of mean expression below which the genes are not considered for ranking, *i.e*. the score for these genes is -∞. We have set *β*~*k*~to be the 25*th*percentile of the mean expression, for each data set *k*. Genes having a higher score are considered more suitable as control genes. As we see from Eq. 1, high variation in gene expression leads to a lower score when mean expression levels are equal. This is one reason we select the most highly variable probeset from the probesets representing the same gene, in order to encompass the worst-case scenario. Note also that there is no need to normalize the scores to make them comparable across data sets, because they are used solely for ranking the genes within the same data set. Finally, having computed the scores for all the genes within a data set, we order the genes from high to low values of the scores, with ties resolved by ordering by the mean expression (from high to low). From this perspective, the scores can be seen as defining classes of equivalence among genes: all the genes in the same class (having the same score) are equally useful as normalization genes. By using the second ordering criterion, we can select control genes with a desired expression level (examples of classes of equivalence are the equal score levels in Figure [2](#F2){ref-type="fig"}).

![**Scatter plots of standard deviation versus mean log-intensity for BWH, NKI and EXPO-breast data sets, respectively**. The shading codes the gene stability scores, with darker colors indicating higher scores. These three data sets are from different microarray platforms. The light gray points indicate the discarded genes (those with mean expression level below the *β*value -- see Eq. 1). The curves correspond to equal score levels and are one score unit apart.](1471-2105-10-42-2){#F2}

Figure [2](#F2){ref-type="fig"} displays the influence of the mean expression level and the standard deviation on the gene score. All genes located on the curves have the same score value (they belong to the same equivalence class). Two consecutive curves are separated by one score unit.

Using this stability score, we ranked the genes from each data set, obtaining the lists that will be later combined. An excerpt from the ten lists for the breast cancer data sets is shown in Table [2](#T2){ref-type="table"} (first ten columns).

###### 

Top 20 control genes from the ten breast cancer data sets and top 20 genes from the aggregated list (Meta column)

  BWH      EMC         JRH2     MGH      NKI         STOCK    TGIF1       UNC       UPP      EXPO-breast   Meta
  -------- ----------- -------- -------- ----------- -------- ----------- --------- -------- ------------- -----------
  RPL37A   PPIA        RPL41    ZNF557   UBC         RPS11    RPL41       RPS10     RPL9     CALM2         RPL37A
  RPL41    CALM2       RPL39    CDR1     UBB         RPS24    RPL37A      RPS18     RPL37A   HNRPA1        RPL27A
  RPS18    SRP14       RPL23A   PPP1R2   OAZ1        RPL9     EEF1A1      RPLP1     ACTG1    NACA          RPS18
  RPL39    RPL37A      RPL37A   TCN2     DYNLL1      RPL37A   RPL30       RPS11     RPL27A   UBA52         RPL30
  RPL23A   RPS18       EEF1A1   SSBP1    RAPSN       RPL41    RPL39       RPS23     CFL1     LAPTM4A       RPL41
  RPL9     RPL30       RPS23    RPL27A   PCBP1       RPL27A   PPIA        RPL37A    RPS11    RPL27A        CALM2
  RPLP1    RPL27A      RPS27    RPS3     KCNH3       RPL39    ACTG1       RPL11     RPS13    RPL30         RPL27
  RPS27    RPS11       CALM2    BRCC3    RPL3        RPLP1    CFL1        RPS15     RPL27    RPL9          K-ALPHA-1
  RPL27A   RPL39       RPS18    PTMA     RPL8        UBB      RPS23       RPL14     RPL41    RPL31         RPS11
  RPL30    RPS15       ACTG1    ABCF2    MYL6        RPS15A   RPL10       NACA      RPS18    RPL37         RPL39
  RPS29    RPS24       RPL10    PCDH18   RPL14       CALM2    CALM2       RPL36AL   RPS15    RPS11         RPS13
  ACTG1    RPL32       RPS24    LAX1     RPL7A       NACA     RPS11       UBA52     RPL6     RPS29         NACA
  CALM2    RPS15A      RPS15A   TPMT     FAU         RPL30    HNRPA1      NEDD8     RPLP1    RPS24         RPL23A
  RPS13    RPLP1       RPL32    GALE     ARF1        CFL1     RPL6        PCBP1     RPL32    RPS13         RPS24
  HNRPA1   RPL9        RPL27A   MTCH1    CCT3        RPS13    RPL23A      NDUFB2    RPL31    RPS21         HNRPA1
  RPS24    UBB         UBB      ATP5G2   PSAP        RPS3A    K-ALPHA-1   HNRPM     RPL39    UBB           RPL9
  RPL31    K-ALPHA-1   RPS29    SF3B2    CD81        RPL37    RPS18       HNRPC     UBB      RPS27A        RPLP1
  RPL34    RPS13       RPL30    SND1     SQSTM1      RPS18    EEF1G       NDUFB8    RPS24    RPS15         RPL32
  RPS15A   RPL27       PPIA     RPL5     K-ALPHA-1   RPL27    TUBA6       ATP5J2    RPS27    RPL32         LAPTM4A
  RPS21    FAU         CFL1     SKAP2    CALR        RPL24    RPS3A       TARDBP    DDX5     RPL24         RPS15A

### Combining results from different data sets

Once genes are ranked according to their scores in each data set (lower ranks correspond to higher scores), the natural next step is to combine these rankings into a global ranked list. We combine the ranks of the genes rather than their scores to avoid normalizing the scores across different data sets, thereby achieving platform-independence. To this end we use the *rank product score*\[[@B16]\], which is a fast and efficient method for combining ranked lists. It computes, for each gene *i*∈ *G*, a new score

$$R_{i} = \left( {\prod\limits_{k}{\text{rank}_{k}(i)}} \right)^{\frac{1}{n_{i}}},$$

where rank~*k*~(*i*) is the rank of *s*~*ik*~, the score for gene *i*in data set *k*(topmost gene has the rank 1), and *n*~*i*~is the number of data sets in which the gene *i*appears. The final list is obtained by sorting the genes in increasing order of *R*~*i*~. The top 20 genes from the aggregated breast cancer list are given in the \'Meta\' (last) column of Table [2](#T2){ref-type="table"}.

### Validation of the aggregated lists

There is no absolute criterion by which one can judge the quality of the resulting lists. Rather, the aggregated list could be used to select from the top genes (100, for example) those genes that also satisfy further conditions of the specific application.

We can, however, have a subjective impression of the validity of the aggregated list by visualizing the resulting top genes in data sets not used for producing the list. We obtained a list of the top 100 genes by applying the method described above on eight of the ten data sets, leaving NKI and UPP aside as validation sets. The top 100 genes in both validation sets (different microarray platforms) are plotted in Figure [3](#F3){ref-type="fig"}. As a comparison, we also include the five control genes used in \[[@B17]\] (represented as triangles in the figure). It is seen that the genes are generally concentrated in the lower right part of the plot, corresponding to high mean expression levels and low variance. There is a notable difference between the quality of the results (given by the concentration of the control genes in the lower right corner) on the two platforms, due to the fact that most of the data sets used for gene selection are from Affymetrix platforms. While the top 100 lists contain genes with high stability scores on the Affymetrix platforms (the UPP data set), on the custom Agilent platform (NKI) there are a number of genes that are missed. Nevertheless, those selected still function well as control genes.

![**Scatter plots of standard deviation versus mean log-intensity for two validation data sets (from left to right: NKI and UPP)**. The top 100 breast cancer control genes resulting from aggregating eight data sets are plotted as circles. Triangles correspond to the five control genes used in \[[@B17]\] (NKI does not contain the ACTB gene).](1471-2105-10-42-3){#F3}

Control genes lists
-------------------

We have analyzed ten different data sets which have samples hybridized on different versions of Agilent and Affymetrix platforms. Using our proposed method, we compiled two different lists of candidate control genes: one specific to breast cancer \[see Additional file [1](#S1){ref-type="supplementary-material"}\] and one resulting from the analysis of eight different types of cancer, thus applicable to cancers in general \[see Additional file [2](#S2){ref-type="supplementary-material"}\]. From the breast cancer list we selected two new control genes which were validated in an RT-QPCR assay that also included five previously used control genes (ACTB, TFRC, GUSB, RPLP0 and GAPDH -- see \[[@B17]\]) and breast cancer-related genes (*e.g*. ESR1, ERBB2, AURKA, *etc*.). The RT-QPCR results confirm the findings from the microarray analysis and show that more stably expressed control genes can be selected by applying the criteria mentioned above. Also, they provide empirical evidence supporting the working hypothesis that PCR control genes can be selected from microarray data.

The list of the top 50 control genes obtained from the ten breast cancer data sets is given in Table [3](#T3){ref-type="table"}. More comprehensive lists, including one containing the top 2000 candidate breast cancer genes and a similar list compiled from eight different types of cancer, are available \[see Additional file [1](#S1){ref-type="supplementary-material"} and Additional file [2](#S2){ref-type="supplementary-material"}\]. In the case of breast cancer control genes, it is interesting to note that some of the \"classical\" genes (*e.g*. ACTB, GAPDH, TFRC) are not among the top 50.

###### 

Top 50 control genes as resulting from aggregating the ten breast cancer data sets. Two genes -- RPS11 and UBB -- were selected as control genes and validated by RT-PCR

  Rank   Gene symbol   Gene ID   Description
  ------ ------------- --------- ------------------------------------------------------------------------------------------------------------------
  1      RPL37A        6168      ribosomal protein L37a
  2      RPL27A        6157      ribosomal protein L27a
  3      RPS18         6222      ribosomal protein S18
  4      RPL30         6156      ribosomal protein L30
  5      RPL41         6171      ribosomal protein L41
  6      CALM2         805       calmodulin 2 (phosphorylase kinase, delta)
  7      RPL27         6155      ribosomal protein L27
  8      K-ALPHA-1     10376     alpha tubulin
  9      **RPS11**     6205      ribosomal protein S11
  10     RPL39         6170      ribosomal protein L39
  11     RPS13         6207      ribosomal protein S13
  12     NACA          4666      nascent-polypeptide-associated complex alpha polypeptide
  12     RPL23A        6147      ribosomal protein L23a
  14     RPS24         6229      ribosomal protein S24
  15     HNRPA1        3178      heterogeneous nuclear ribonucleoprotein A1
  16     RPL9          6133      ribosomal protein L9
  17     RPLP1         6176      ribosomal protein, large, P1
  18     RPL32         6161      ribosomal protein L32
  19     LAPTM4A       9741      lysosomal-associated protein transmembrane 4 alpha
  20     RPS15A        6210      ribosomal protein S15a
  21     DYNLL1        8655      dynein, light chain, LC8-type 1
  22     ACTG1         71        actin, gamma 1
  23     TUBA6         84790     tubulin, alpha 6
  24     SRP14         6727      signal recognition particle 14kDa (homologous Alu RNA binding protein)
  25     MYL6          4637      myosin, light chain 6, alkali, smooth muscle and non-muscle
  26     RPL24         6152      ribosomal protein L24
  27     FAU           2197      Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30
  28     RPL31         6160      ribosomal protein L31
  29     RPS15         6209      ribosomal protein S15
  30     MTCH1         23787     mitochondrial carrier homolog 1 (C. elegans)
  31     **UBB**       7314      ubiquitin B
  32     RPL37         6167      ribosomal protein L37
  33     HMGN2         3151      high-mobility group nucleosomal binding domain 2
  34     RPS27         6232      ribosomal protein S27 (metallopanstimulin 1)
  35     GDF8          2660      growth differentiation factor 8
  36     RPL38         6169      ribosomal protein L38
  37     RPS29         6235      ribosomal protein S29
  38     SULT1C2       27233     sulfotransferase family, cytosolic, 1C, member 2
  39     RPL6          6128      ribosomal protein L6
  40     UBC           7316      ubiquitin C
  41     UBA52         7311      ubiquitin A-52 residue ribosomal protein fusion product 1
  42     MRFAP1        93621     Mof4 family associated protein 1
  43     HNRPK         3190      heterogeneous nuclear ribonucleoprotein K
  44     PARK7         11315     Parkinson disease (autosomal recessive, early onset) 7
  45     PSMC1         5700      proteasome (prosome, macropain) 26S subunit, ATPase, 1
  46     LOC158572     158572    hypothetical protein LOC158572
  47     RPS8          6202      ribosomal protein S8
  48     ATP5A1        498       ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle
  49     EIF4H         7458      eukaryotic translation initiation factor 4H
  50     CD63          967       CD63 molecule

Evaluation of control genes by RT-QPCR
--------------------------------------

Motivated by the consistency of the selection process for suitable control genes among different microarray platforms, we performed a small scale RT-QPCR experiment to test the performance of two new control genes along with a number of more commonly used control genes. In this experiment, RNA was isolated from 25 cryo-preserved breast cancer samples and the expression of 47 genes was measured by RT-QPCR \[[@B18]\]. Test genes were selected according to their relatedness to proliferation or estrogen receptor functions. Some of the test genes had been previously identified and used for characterizing primary breast cancers \[[@B17]\]. Two genes, RPS11 and UBB, ranked 9 and 31 in Table [3](#T3){ref-type="table"} respectively, were compared to five additional control genes and to a number of test genes previously measured by \[[@B17]\]. Mean raw expression values of all candidate control and test genes were plotted against standard deviations of each gene (Figure [4](#F4){ref-type="fig"}). The raw Ct (cycle threshold) value is the number of PCR cycles required for the fluorescence signal to cross the background threshold, so that low Ct values correspond to high expression levels. RPS11 and UBB are clearly among the most stably expressed genes, as their standard deviations are both quite low. Other genes frequently used as control genes are also shown. For comparison, mean expression and standard deviation of several test genes are also indicated. The expression of most test genes is much more variable than UBB and RPS11.

![**RT-QPCR experiment**. Standard deviation as a function of the mean expression level (expressed as raw Ct values) of 47 genes in a RT-QPCR experiment. Higher expression levels correspond to smaller raw Ct values. Control genes are represented by triangles, test genes by circles. The new control genes RPS11 and UBB are in the lower left corner.](1471-2105-10-42-4){#F4}

The two new control genes, together with RPLP0, offer the best trade-off between mean expression level and variability, while others like ACTB or TFRC are less stably expressed and therefore seem less suitable for use as normalization genes.

Discussion
==========

We propose a new approach which leverages publicly available microarray data to produce lists of candidate control genes for RT-QPCR. Our method is independent of the microarray platform or normalization methodology, and is able to cope with gene lists that overlap only partially. After screening thousands of genes (generally more than 10,000 genes in each data set), we have produced two separate lists of candidate genes: one specific to breast cancer and one generally applicable to different types of cancer. We do not consider these lists as generally applicable, as the data used do not allow such generalization. Different pathologies may have a different impact on the control genes and some of the control genes we selected may become ineffective in the case of a disease which affects their particular functions. On the other hand, more diverse data should be used if the goal is finding global control genes. The list of the top 50 breast cancer control genes (Table [3](#T3){ref-type="table"}) is dominated by ribosomal proteins. This finding is consistent with the fact that ribosomes are a major component of basic physiologic processes in all the cells and not a primary target of changing conditions. Other genes present among the first 50 genes code for protein turnover (ubiquitin), tubulin-related proteins or actins, structures which are required in all living cells.

Our results are supported by recent findings of de Jonge *et al*. \[[@B5]\], who used a different ranking method. In addition, the lists of control gene candidates for breast cancer and for diverse types of cancer are similar \[see Additional file [1](#S1){ref-type="supplementary-material"} and Additional file [2](#S2){ref-type="supplementary-material"}\], as a large number of the top ranked genes belong to the same functional category (ribosomal genes, protein turnover).

Another important finding is that some of the commonly used control genes in breast cancer (ACTB and TFRC) appear to be less stable than previously assumed. This has an impact on the normalization strategy of the QPCR measurements: indeed, in our more recent experiments we have chosen to use the mean of RPLP0, RPS11 and UBB (on the log~2~scale) for normalizing the expression of test genes.

Finally, we would like to emphasize that these two lists should not be taken in an absolute sense: a gene in top 10 is not necessarily a better choice than a gene in the top 20 to 30. But we do consider it to be definitely a better candidate than a gene not in top 100. Nor do we consider the resulting ranking as providing a solution to the problem of finding normalization genes in all contexts. Rather, the lists produced through this process are meant to guide the choice of control genes while also taking into consideration the specific requirements of any individual analysis. Depending on the planned application, other parameters must be considered. For example, short amplicons or intron-spanning primers must be used when the starting RNA is considerably degraded or when residual DNA contaminations might affect QPCR. The final choice of control genes should be made not by blind adherence to the ranked list, but be imposed by the intended application.

Conclusion
==========

Starting from clearly defined criteria, we have designed a novel method for ranking the candidate genes for their suitability as control genes in RT-QPCR experiments. The genes from a data set were ranked according to their stability score, which represented a trade-off between gene\'s average expression level and its variance. Finally, the rankings from several data sets were combined into a list of candidate genes, with higher ranked genes being considered to be more suitable as control genes. The proposed approach had the advantage of being platform- and normalization- independent and of not being restricted to only the list of common genes across all data sets.

By applying the proposed method to two particular collections of data sets we were able to produce two lists of candidate genes from which control genes for either breast cancer or more diverse cancer could be easily selected. Two new control genes for breast cancer -- UBB and RPS11 -- have been identified and validated by RT-QPCR.

Our results support the hypothesis that selecting control genes for QPCR from microarray data is feasible.
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###### Additional file 1

**Top 2000 breast cancer candidate control genes.** Excel file containing top 2000 genes as resulted from combining the ten breast cancer data sets.
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Click here for file

###### Additional file 2

**Top 2000 diverse cancer candidate control genes.** Excel file containing top 2000 genes as resulted from combining the eight different types of cancer from the EXPO data set.
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Acknowledgements
================

This work has been funded by the Swiss National Science Foundation through the National Centre for Competence in Research (Molecular Oncology (MD, VP and PW)) and the National Centre for Competence in Research (Plant Survival (DRG)), and by the Swiss Cancer League (Project OCS 01704-04-2005 (RJ and MD)).
